BioStock: Elicera's CEO: "iTANK partnering is intensifying"

Elicera Therapeutics is in an advantageous position, both in terms of financial flexibility and the ability to enter into new collaboration agreements. The cell and gene therapy company has the finances to run all programmes at full speed until the H1 2024. In addition, the company recently concluded the first international collaboration regarding iTANK, and work is now underway to secure more similar agreements. BioStock contacted CEO and co-founder Jamal El-Mosleh to find out more about the priorities going forward.

Read the full interview with Elicera’s CEO Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2022/11/eliceras-ceo-itank-partnering-is-intensifying

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/